研究

Akashi Y, Miki K, Kiba K, Yamamoto Y, Fujita K, Hirayama A.

Relationship Between the First Undisturbed Sleep Period and Diuretic and Urine Storage States of the First Void After Sleep

Fujimoto S, Hatano K, Banno E, Motooka D, De Velasco MA, Kura Y, Toyoda S, Hashimoto M, Adomi S, Minami T, Yoshimura K, Oka T, Hata J, Matsushita M, Takao T, Takada S, Tsujimura A, Kojima Y, Obara W, Nakamura S, Uemura H, Nonomura N, Fujita K.

Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men

Nishimoto M, De Velasco MA, Yamamoto Y, Fujimoto S, Akashi Y, Toyoda S, Hashimoto M, Adomi S, Banno E, Saito Y, Minami T, Hirayama A, Yoshimura K, Uemura H, Fujita K.

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate

Fukushima T, Tsujino T, Sakamoto M, Takahara K, Komura K, Yanagisawa T, Mori K, Fukuokaya W, Urabe F, Adachi T, Hirasawa Y, Saruta M, Yoshizawa A, Toyoda S, Kawada T, Katayama S, Iwatsuki K, Nakamura K, Nishio K, Nishimura K, Nakamori K, Matsunaga T, Maenosono R, Uchimoto T, Takai T, Hashimoto T, Inamoto T, Fujita K, Araki M, Kimura T, Ohno Y, Shiroki R, Azuma H.

Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impact

Fiala O, Buti S, Fujita K, de Liaño AG, Fukuokaya W, Kimura T, Yanagisawa T, Giannatempo P, Angel M, Mennitto A, Molina-Cerrillo J, Bourlon MT, Soares A, Takeshita H, Calabrò F, Ortega C, Kucharz J, Milella M, Seront E, Park SH, Tural D, Benedetti G, Ürün Y, Battelli N, Melichar B, Poprach A, Buchler T, Kopecký J, Conteduca V, Monteiro FSM, Massari F, Gupta S, Santoni M.

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study

Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I.

Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study

Furukawa J, Kato T, Yamasaki T, Monji K, Tanaka T, Tsuchiya N, Miyagawa T, Yaegashi H, Sano T, Karashima T, Fujita K, Hori JI, Ito T, Kajita M, Tomita Y, Shinohara N, Eto M, Oya M, Uemura H.

Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification

Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H.

Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium

Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Fujimoto S, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H.

Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium

Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Yamana K, Kandori S, Kimura T, Nishiyama N, Bando Y, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Kitamura H, Miyake H, Habuchi T.

Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma

Narita S, Yanagisawa T, Hatakeyama S, Hata K, Fujita K, Ueda T, Tanaka T, Maita S, Chiba S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Numakura K, Saito M, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Iwabuchi I, Suzuki T, Ukimura O, Kimura T, Ohyama C, Nomura K, Habuchi T.

Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy

Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O.

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Tasaki Y, Hamamoto S, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Mimura Y, Sugiyama Y, Unno R, Okada A, Yasui T, Furukawa-Hibi Y.

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study